ArticleInternational journal of cancer2021

Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.

Omar Alhalabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.